New lipid overcomes limitations of Pseudomonas aeruginosa mRNA vaccine by reducing systemic side effects and enhancing local immunity
Background
Pseudomonas aeruginosa is a leading cause of hospital-acquired infections and is known for its strong antibiotic resistance, making it a particularly challenging pathogen to treat. Patients with weakened immune systems who become infected with Pseudomonas aeruginosa face a high risk of progressing to severe diseases such as sepsis or aspiration pneumonia. Despite the urgent need for a vaccine to prevent such infections, no Pseudomonas aeruginosa vaccine has been approved globally. Recently, messenger RNA (mRNA) and lipid nanoparticle (LNP) technology have emerged as promising alternatives, but existing delivery systems have shown significant limitations.
Conventional LNP formulations are typically designed to maximize gene expression in the body. The lipid components used in vaccines such as those for COVID-19 tend to spread antigens systemically after intramuscular injection. This has raised ongoing concerns about off-target immune responses in organs such as the liver and spleen, potentially leading to systemic side effects. At the same time, the proportion of LNPs reaching local lymph nodes, where immune cells are concentrated, is low, which has contributed to reduced efficiency in inducing antibacterial immunity.
Key Findings
The research team developed a novel ionizable lipid, LC3, that restricts antigen expression to localized areas, thereby overcoming the challenges of existing delivery technologies. LC3-based LNPs exhibit a unique distribution profile, remaining localized at the injection site rather than spreading throughout the body after intramuscular administration. This characteristic allows for antigen expression to be concentrated at the injection site and adjacent lymph nodes, forming the basis for ensuring vaccine safety.
At the same time, immune stimulation activity at the injection site and lymph nodes is significantly enhanced compared to existing formulations. The research team conducted comparative experiments using SM102-based LNPs, which are widely used in currently commercialized vaccines. Experimental results showed that LC3-based mRNA-LNPs effectively suppressed antigen leakage to systemic organs while significantly increasing the activity of antigen-presenting cells in the body. The combination of localized antigen expression and strong immune stimulation enabled the induction of high levels of antibody formation and immune response with a lower dose than existing formulations.
Significance and Prospects
The newly developed ionizable lipid LC3 opens the possibility for the commercialization of various antibacterial mRNA vaccines that have been delayed due to concerns about side effects. The LNP design technology that optimizes local expression is expected to become a core technology for next-generation vaccine platforms that simultaneously ensure safety and strong immunogenicity. It can also be widely applied in areas such as cancer vaccines and immunotherapies, where localized treatment is essential.
However, to be introduced into clinical practice, clinical trials in humans must be conducted to verify long-term safety and preventive efficacy. Ensuring process technology that maintains the structural stability of LNPs during mass production is also a prerequisite. Additional research to overcome the physical properties of mRNA formulations sensitive to temperature changes and to extend shelf life is expected to provide real-world benefits to patients.
Pseudomonas aeruginosa is a major cause of hospital-acquired infections, yet no licensed vaccine is available. Although mRNA-LNP vaccines offer a flexible platform for antibacterial immunization, conventional formulations are primarily optimized for gene expression and often result in systemic antigen distribution. Here, we developed a novel ionizable lipid, LC3, that enables spatially confined antigen expression following intramuscular administration while enhancing immunostimulatory activity. Compared with SM102-based LNPs, mRNA-LNP
This technology can be usefully applied in the future to protect high-risk patients who are exposed to multidrug-resistant hospital-acquired infections. A representative scenario is the administration of Pseudomonas aeruginosa preventive vaccines to critically ill patients in intensive care units who are on ventilators or have rapidly declining immune function. By limiting immune responses to the injection site, it allows vaccination to be carried out with reduced side effect burden in elderly patients or those with underlying conditions who are vulnerable to systemic immune reactions. It is expected to become a practical means to reduce mortality from acute sepsis caused by hospital-acquired infections and to lower healthcare costs.